Evotec SE (EVO) Price Prediction 2026–2050

Evotec SE operates as a drug discovery and development company with activities in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just – Evotec Biologics, and is developing pharmaceutical products across a range of therapeutic areas including oncology, autoimmune diseases, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious diseases, kidney and liver diseases, respiratory disorders, fibrotic and metabolic diseases, and rare diseases. The company is also pursuing central nervous system (CNS) and cardiometabolic diseases, as well as animal and women health.

Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany, and it was formerly known as Evotec AG, changing its name to Evotec SE in April 2019.

The business engages in collaborations with a variety of institutions and companies, and it serves pharma and biotechnology firms, academic institutions, patient advocacy groups, and venture capital. It has collaboration agreements with Mass General Brigham and Joslin Diabetes Center focusing on cardiometabolic diseases, and partnerships with BMS antiviral, Novo Nordisk cell therapy, University of Oxford, German Cancer Research Center, University Hospital in Hamburg, University of Toronto, Harvard and Yale, Johns Hopkins University, Ospedale San Raffaele, and National University of Singapore, among others. Evotec SE has a global footprint and a portfolio of alliances spanning academia, industry, and healthcare research.

Headquartered in Hamburg, Germany, the company has a long-standing history since its incorporation in 1993 and carries the branding evolution from Evotec AG to Evotec SE in 2019, reflecting its ongoing role in drug discovery and development across international markets.

Evotec SE (EVO) is trading at $3.03 per share and has a market cap of $1.08B. It ranks 2490 by market capitalization within its universe.

The current price sits within a framework defined by known technical levels: a 14-day impulse and trend framework with RSI reading at 50, and moving averages showing SMA50 at $2.82 and SMA200 at $3.31. On the chart, support is identified at $2.70 and resistance at $3.30, with the 30-day price range spanning $2.49 to $3.69.

The long-range forecast envisions a bullish path beyond 2026, with yearly averages rising over time. The 2026 forecast shows a min of $2.31, an average of $3.03, and a max of $4.22, with 2026 sentiment listed as NEUTRAL. From 2028 onward, the outlook becomes strongly bullish, culminating in a 2050 average price of $17.96 and a max of $34.43, supported by a max ROI of 492.7% and a bullish sentiment.

Overall, Evotec SE presents a picture of modest current values with a clear long-term upward trajectory in the forecast, punctuated by periods of neutral sentiment early on and a pronounced bullish stance toward the end of the horizon.

The multi-year forecast shows a bullish trajectory from 2028 through 2050, with average prices climbing from $3.95 in 2028 to $17.96 in 2050. The anticipated price path includes a 2028 average of $3.95 with a 30.3% ROI, a 2029 average of $4.73 with a 56.1% ROI, and a 2030 average of $4.82 with a 59% ROI, illustrating continued upside.

Key milestones include a 2040 average of $8.30 with a 174% ROI and a 2050 average of $17.96 with a 492.7% ROI. The forecast also shows several years of bullish sentiment from 2028 onward, with 2031, 2032, and 2033 all labeled bullish and continuing through 2050. These figures reflect potential upside alongside the underlying uncertainties inherent in any forecast.

These are estimates, not guarantees, and subject to market volatility and other risks. The trajectory suggests meaningful upside over the long term, but actual outcomes may differ from the forecast.